• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly: October 2006 Issue

CenterWatch Monthly: October 2006 Issue

October 16, 2006
CenterWatch Staff

Adaptive Designs Taking Hold

The use of adaptive clinical trial designs has the potential to reduce the size, length and cost of clinical trials. These innovative protocol designs can also reduce the amount of time patients are exposed to the harmful side effects of ineffective treatments. Results gleaned from such studies can be more informative in planning for future trials and may ultimately lead to a shortening of the drug development process. Despite its obvious potential benefits, the technique has many challenges ahead and is not without controversy. The changes ahead will no doubt create new challenges for the entire industry, including investigative sites, data safety monitoring boards (DSMBs), and CROs.

Drug Research Reform Efforts Explored

The mainstream press continues to focus on any scandal, or whiff of controversy, in the drug development process. Sponsors, CROs and stakeholders in drug research should be aware of how regulators and ethicists may want to change the way they conduct research. Academia and bioethicists have been promoting proposals that could radically change the ways drugs are developed. However, some of the proposals are far-fetched and have little chance of being adopted.

Vienna School of Clinical Research Trains PIs in China.

The Vienna School of Clinical Research (VSCR) has run five courses for potential principal investigators in China this summer in the areas of publication in international medical journals, GCP, protocol design and development, and ethical aspects of clinical research. VSCR was founded in 2001 to raise the level of professionalism in clinical research, especially in Central and Eastern Europe and developing countries.

Eye On Breast Cancer

Breast cancer is the second most frequently diagnosed cancer in women after nonmelanoma skin cancer, and the second leading cause of cancer deaths after lung cancer. According to the American Cancer Society, estimated U.S. incidence in 2006 is 214,640 new cases and 41,430 deaths from breast cancer. The World Health Organization estimates that there will be 1.2 million diagnoses of breast cancer this year worldwide. During her lifetime, a woman’s chance of developing invasive breast cancer is approximately 1 in 8.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing